Suppr超能文献

玻璃体内注射贝伐单抗剂量对早产儿视网膜病变视网膜血管进展的影响。

The Effect of Intravitreal Bevacizumab Dose on Retinal Vascular Progression in Retinopathy of Prematurity.

作者信息

Bayramoglu Sadik Etka, Sayin Nihat

机构信息

Tertiary ROP Clinic, Health Science University Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey.

出版信息

Ophthalmologica. 2022;245(2):161-172. doi: 10.1159/000521070. Epub 2021 Nov 29.

Abstract

INTRODUCTION

In this study, we investigated the effect of drug dose on the progression of retinal vascularization in eyes treated with different doses of intravitreal bevacizumab (IVB).

METHODS

The patient charts of 259 eyes of 142 patients who were administered 0.3125 mg or 0.625 mg IVB as primary therapy for type 1 retinopathy of prematurity (ROP) or aggressive ROP (A-ROP) were retrospectively evaluated. Eighty-four eyes of 42 infants met all study inclusion criteria and underwent further morphological evaluation. Eyes treated with 0.3125 mg and 0.625 mg bevacizumab were grouped as the low dose and standard dose groups, respectively. Horizontal disc diameter (DD), optic disc-to-fovea distance (FD), and the length of temporal retinal vascularization (LTRV) were measured on pretreatment photographs (PPs) and final fluorescein angiography (FA) images. LTRV, measured in pixels, was converted to DD and FD units and analyzed. All PPs and FA images were captured with 130° PanoCam Pro camera. The difference between final LTRV and pretreatment LTRV was defined as the difference of LTRV. The ratio of difference of LTRV to pretreatment LTRV was defined as the rate of increase of LTRV.

RESULTS

Of the 255 eyes, re-treatment rate before 55 weeks postmenstrual age (PMA) was 23% in the eyes treated with 0.3125 mg IVB and 19% in the eyes treated with 0.625 mg IVB (p = 0.362). Of the 42 infants included for further morphological evaluation, the median age at the time of treatment was 36 (35-38) weeks PMA, and the median age at the time of FA imaging was 66 (62-75) weeks PMA. While the difference of LTRV by unit of DD was higher in the low dose group (p = 0.017), this difference was similar between groups by unit of FD (p = 0.412). The ratio of the increase of the LTRV was similar between groups by units of DD and FD (p = 0.081, p = 0.390; respectively). The FD/DD ratio was 4.13 ± 0.49 and 3.26 ± 0.33 at the pretreatment and final sessions, respectively (p = 0.000).

CONCLUSION

The ratio of FD to DD decreased significantly with increasing age. The additional treatment rate and progression of retinal vascularization by unit of FD were similar between the groups. The difference of LTRV by unit of DD was higher in the low dose group. The usage of dif-ferent formulas and methods may affect the evaluation of the progression of retinal vascularization.

摘要

引言

在本研究中,我们调查了不同剂量玻璃体内注射贝伐单抗(IVB)治疗的眼睛中药物剂量对视网膜血管化进程的影响。

方法

回顾性评估了142例患者的259只眼睛的病历,这些患者接受了0.3125mg或0.625mg IVB作为1型早产儿视网膜病变(ROP)或侵袭性ROP(A-ROP)的主要治疗。42例婴儿的84只眼睛符合所有研究纳入标准并接受了进一步的形态学评估。接受0.3125mg和0.625mg贝伐单抗治疗的眼睛分别分为低剂量组和标准剂量组。在治疗前照片(PPs)和最终荧光素血管造影(FA)图像上测量水平视盘直径(DD)、视盘至黄斑中心凹距离(FD)和颞侧视网膜血管化长度(LTRV)。以像素为单位测量的LTRV被转换为DD和FD单位并进行分析。所有PPs和FA图像均使用130°全景相机拍摄。最终LTRV与治疗前LTRV的差异定义为LTRV差异。LTRV差异与治疗前LTRV的比值定义为LTRV增加率。

结果

在255只眼睛中,月经后年龄(PMA)55周前接受0.3125mg IVB治疗的眼睛再治疗率为23%,接受0.625mg IVB治疗的眼睛再治疗率为19%(p = 0.362)。在纳入进一步形态学评估的42例婴儿中,治疗时的中位年龄为PMA 36(35 - 38)周,FA成像时的中位年龄为PMA 66(62 - 75)周。虽然低剂量组以DD为单位的LTRV差异更高(p = 0.017),但以FD为单位时两组之间的差异相似(p = 0.412)。以DD和FD为单位时,两组之间LTRV增加的比值相似(分别为p = 0.081,p = 0.390)。治疗前和最终检查时FD/DD比值分别为4.13±0.49和3.26±0.33(p = 0.000)。

结论

随着年龄增长,FD与DD的比值显著降低。两组之间以FD为单位的额外治疗率和视网膜血管化进程相似。低剂量组以DD为单位的LTRV差异更高。不同公式和方法的使用可能会影响视网膜血管化进程的评估。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验